The role of GSK3 in Alzheimer disease

Brain Research Bulletin

Volumn 80, Issue 4-5, 2009, Pages 248-250

  Hernández, Félix ^a   Barreda, Elena Gómez de ^a   Fuster Matanzo, Almudena ^a   Goñi Oliver, Paloma ^a   Lucas, José J ^a   Avila, Jesús ^a  

^a CSIC   (Spain)

Author keywords

Alzheimer disease; Dentate gyrus; GSK3; Tau protein

Indexed keywords

AMYLOID BETA PROTEIN; GLYCOGEN SYNTHASE KINASE 3;

ALZHEIMER DISEASE; ENZYME ACTIVITY; FAMILIAL DISEASE; GENE MUTATION; HUMAN; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

ALZHEIMER DISEASE; ANIMALS; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MICE; PHOSPHORYLATION; TAU PROTEINS;

EID: 70349420866     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2009.05.017     Document Type: Review

References (33)

1. Aberle H., Bauer A., Stappert J., Kispert A., and Kemler R. beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J. 16 (1997) 3797-3804
2. Alonso A.D., Grundke-Iqbal I., Barra H.S., and Iqbal K. Abnormal phosphorylation of tau and the mechanism of Alzheimer neurofibrillary degeneration: sequestration of microtubule-associated proteins 1 and 2 and the disassembly of microtubules by the abnormal tau. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 298-303
3. Alzheimer A. Über eine eigenartige erkrankung der hirnrinde. Allg Z Psychiatrie Psychisch-Gerichtz Med. 64 (1907) 146-148
4. Arriagada P.V., Growdon J.H., Hedley-Whyte E.T., and Hyman B.T. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 42 (1992) 631-639
5. Baki L., Shioi J., Wen P., Shao Z., Schwarzman A., Gama-Sosa M., Neve R., and Robakis N.K. PS1 activates PI3K thus inhibiting GSK-3 activity and tau overphosphorylation: effects of FAD mutations. EMBO J. 23 (2004) 2586-2596
6. Braak H., and Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82 (1991) 239-259
7. Bryja V., et al. The extracellular domain of Lrp5/6 inhibits noncanonical Wnt signaling in vivo. Mol. Biol. Cell 20 (2009) 924-936
8. Cross D.A., Alessi D.R., Cohen P., Andjelkovich M., and Hemmings B.A. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378 (1995) 785-789
9. Cselenyi C.S., Jernigan K.K., Tahinci E., Thorne C.A., Lee L.A., and Lee E. LRP6 transduces a canonical Wnt signal independently of Axin degradation by inhibiting GSK3's phosphorylation of beta-catenin. Proc. Natl. Acad. Sci. U.S.A. 105 (2008) 8032-8037
10. De Ferrari G.V., et al. Common genetic variation within the low-density lipoprotein receptor-related protein 6 and lateonset Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 104 (2007) 9434-9439
11. Delacourte A., et al. The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease. Neurology 52 (1999) 1158-1165
12. Engel T., Hernandez F., Avila J., and Lucas J.J. Full reversal of Alzheimer's disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3. J. Neurosci. 26 (2006) 5083-5090
13. Engel T., Lucas J.J., Gomez-Ramos P., Moran M.A., Avila J., and Hernandez F. Cooexpression of FTDP-17 tau and GSK-3beta in transgenic mice induce tau polymerization and neurodegeneration. Neurobiol. Aging 27 (2006) 1258-1268
14. Gomez-Ramos A., Diaz-Hernandez M., Cuadros R., Hernandez F., and Avila J. Extracellular tau is toxic to neuronal cells. FEBS Lett. 580 (2006) 4842-4850
15. Gomez-Ramos A., Diaz-Hernandez M., Rubio A., Miras- Portugal M.T., and Avila J. Extracellular tau promotes intracellular calcium increase through M1 and M3 muscarinic receptors in neuronal cells. Mol. Cell. Neurosci. 37 (2008) 673-681
16. Goni-Oliver P., Lucas J.J., Avila J., and Hernandez F. N-terminal cleavage of GSK-3 by calpain: a new form of GSK-3 regulation. J. Biol. Chem. 282 (2007) 22406-22413
17. Hardy J., and Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 (2002) 353-356
18. Hernandez F., and Avila J. The role of glycogen synthase kinase 3 in the early stages of Alzheimer's' disease. FEBS Lett. 582 (2008) 3848-3854
19. Hernandez F., Borrell J., Guaza C., Avila J., and Lucas J.J. Spatial learning deficit in transgenic mice that conditionally over-express GSK-3beta in the brain but do not form tau filaments. J. Neurochem. 83 (2002) 1529-1533
20. Jin K., Peel A.L., Mao X.O., Xie L., Cottrell B.A., Henshall D.C., and Greenberg D.A. Increased hippocampal neurogenesis in Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 343-347
21. Leissring M.A. The AbetaCs of Abeta-cleaving proteases. J. Biol. Chem. 283 (2008) 29645-29649
22. Lucas J.J., Hernandez F., Gomez-Ramos P., Moran M.A., Hen R., and Avila J. Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J. 20 (2001) 27-39
23. Magdesian M.H., Carvalho M.M., Mendes F.A., Saraiva L.M., Juliano M.A., Juliano L., Garcia-Abreu J., and Ferreira S.T. Amyloid-beta binds to the extracellular cysteine-rich domain of Frizzled and inhibits Wnt/beta-catenin signaling. J. Biol. Chem. 283 (2008) 9359-9368
24. Parsons C.G., Stoffler A., and Danysz W. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse. Neuropharmacology 53 (2007) 699-723
25. Phiel C.J., Wilson C.A., Lee V.M., and Klein P.S. GSK-3alpha regulates production of Alzheimer's disease amyloidbeta peptides. Nature 423 (2003) 435-439
26. Price D.L., and Sisodia S.S. Mutant genes in familial Alzheimer's disease and transgenic models. Annu. Rev. Neurosci. 21 (1998) 479-505
27. Schaffer B.A., et al. Association of GSK3B with Alzheimer disease and frontotemporal dementia. Arch. Neurol. 65 (2008) 1368-1374
28. Seri B., Garcia-Verdugo J.M., Collado-Morente L., McEwen B.S., and Alvarez-Buylla A. Cell types, lineage, and architecture of the germinal zone in the adult dentate gyrus. J. Comp. Neurol. 478 (2004) 359-378
29. Takashima A., et al. Presenilin 1 associates with glycogen synthase kinase-3beta and its substrate tau. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 9637-9641
30. Tamai K., et al. LDL-receptor-related proteins in Wnt signal transduction. Nature 407 (2000) 530-535
31. Townsend M., Mehta T., and Selkoe D.J. Soluble Abeta inhibits specific signal transduction cascades common to the insulin receptor pathway. J. Biol. Chem. 282 (2007) 33305-33312
32. White A.R., et al. Degradation of the Alzheimer disease amyloid beta-peptide by metal-dependent up-regulation of metalloprotease activity. J. Biol. Chem. 281 (2006) 17670-17680
33. Zhao C., Deng W., and Gage F.H. Mechanisms and functional implications of adult neurogenesis. Cell 132 (2008) 645-660